ARDS
282
34
41
128
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
18 trials with published results (6%)
Research Maturity
128 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.7%
16 terminated out of 282 trials
88.9%
+2.3% vs benchmark
5%
14 trials in Phase 3/4
14%
18 of 128 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 128 completed trials
Clinical Trials (282)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19
Mechanical Power and Mortality in Mechanically Ventilated Adults
Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
TwichView-guided Atricurium Dose Adjustment Trial
Respiratory Knowledge Portal Computer and Phone Application to Improve Quality of Mechanical Ventilation by Reducing the Number of Ventilator Associated Events, Injury Created by the Ventilator and Unsafe Setting of Alarms.
Incremental and Decremental PEEP Titration by Diverse Strategies in Subjects With ARDS: A Prospective Physiological Study
Machine Learning Prediction of Mortality After Prone Positioning in ARDS
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress
Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure
One-year Outcomes in Survivors of the Severe COVID-19 Pneumonia (CO-Qo-ICU)
Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals